Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433219 · ClinicalTrials.gov registry record · Phase 2
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
A Phase 2 study of Ovarian Cancer, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT06433219 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 63 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06433219, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
Conditions Studied
Interventions
- DRUG Niraparib
- DRUG Tuvusertib (M1774)
- DRUG Lartesertib (M4076)
Study Locations (20)
Other
- Chris O'Brien Lifehouse - Camperdown
- St George Private Hospital - Kogarah
- Liverpool Hospital - PARENT - Liverpool
- Cliniques Universitaires Saint-Luc - STL - Brussels
- UZ Leuven - Leuven
- Ålborg Universitets Hospital - PARENT - Aalborg
- Rigshospitalet - Copenhagen
- Sjaellands Universitetshospital - other - Odense
- ICO - Site Paul Papin - service d'oncologie medicale - Angers
- Centre Francois Baclesse - Service d'Oncologie Medicale - Caen
- Centre Oscar Lambret - service de cancerologie gynecologique - Lille
New York
- Memorial Sloan Kettering Cancer Center - New York
- Icahn School of Medicine at Mount Sinai PRIME - Mount Sinai - PRIME - New York
Virginia
- Next Oncology - Virginia - Fairfax
- Virginia Cancer Specialists, PC - Fairfax
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- University of California San Francisco - UCSF Medical Center - San Francisco
Georgia
- Centricity Research Cancer Center - DBA CRRI John B. Amos Cancer Center Research - Columbus
Illinois
- University of Chicago Comprehensive Cancer Center at Silver Cross - Carolyn J. Czerkies Pavilion - Chicago
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433219
The ClinicalTrials.gov registry entry for NCT06433219 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Niraparib is the first listed.
NCT06433219 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, Virginia.
Frequently Asked Questions
What is clinical trial NCT06433219 about?
NCT06433219 is a clinical study titled "Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)". The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previous...
What is the current status of trial NCT06433219?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2024-10-30. Estimated completion is 2026-06-26.
What conditions does trial NCT06433219 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06433219?
The interventions under investigation include: Niraparib (DRUG), Tuvusertib (M1774) (DRUG), Lartesertib (M4076) (DRUG).
Who is sponsoring clinical trial NCT06433219?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433219 being conducted?
This trial has 20 study locations across Arkansas, California, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.